Literature DB >> 14649218

CJC-1131. ConjuChem.

Nick Giannoukakis1.   

Abstract

ConjuChem is developing CJC-1131, a drug affinity complex conjugate of glucagon-like peptide 1 for the potential treatment of type 2 diabetes. In August 2003, a phase I/II trial was completed and a phase II trial was expected to begin in October.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14649218

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  4 in total

Review 1.  Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.

Authors:  Lei Diao; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

2.  Regulation of BAX/BCL2 gene expression in breast cancer cells by docetaxel-loaded human serum albumin nanoparticles.

Authors:  Marzieh Kordezangeneh; Shiva Irani; Reza Mirfakhraie; Mehdi Esfandyari-Manesh; Fatemeh Atyabi; Rassoul Dinarvand
Journal:  Med Oncol       Date:  2015-06-23       Impact factor: 3.064

3.  A platform for efficient, thiol-stable conjugation to albumin's native single accessible cysteine.

Authors:  Mark E B Smith; Mikael B Caspersen; Eifion Robinson; Maurício Morais; Antoine Maruani; João P M Nunes; Karl Nicholls; Malcolm J Saxton; Stephen Caddick; James R Baker; Vijay Chudasama
Journal:  Org Biomol Chem       Date:  2015-06-25       Impact factor: 3.876

Review 4.  Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics.

Authors:  Kine Marita Knudsen Sand; Malin Bern; Jeannette Nilsen; Hanna Theodora Noordzij; Inger Sandlie; Jan Terje Andersen
Journal:  Front Immunol       Date:  2015-01-26       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.